The US Medicare Payment Advisory Commission’s first public presentation on analyses based on Part D rebate data show that drug price inflation in the program is, in fact, relatively high – even after accounting for rebates.
In a presentation during MedPAC’s 7-8 April meeting, MedPAC staff showed a comparison of the gross Part D drug spending trends that the commission has relied on in the past versus net pricing taking into account rebates, which is based on data that MedPAC only began receiving recently following legislation enacted at the end of 2020
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?